Using air filtration to slow heart disease progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This double-blind, randomized, crossover trial investigates whether long-term indoor air filtration can slow the progression of atherothrombosis in adults with a history of ischemic heart disease. The study will involve 112 participants who will undergo two 9-month periods of either true HEPA filtration or sham filtration, separated by a 3-month wash-out period. Researchers will monitor indoor air quality and collect health data, including vascular function and blood pressure, to assess the impact of reduced indoor fine particulate matter exposure on heart disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 65 and 84 years old;
* Weight ≥ 110 pounds;
* Nonsmokers for at least 1 year;
* Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;
* Both English and Spanish speaking participants will be included in the recruitment;
* Live in the Los Angeles County.

Exclusion Criteria:

* Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;
* Currently have active cancer treatments;
* The residential house has already had HEPA filters;
* Participants will move out from the current residential address in the next 2 years;
* Participants will spend more than 1 month living outside the primary home;
* Have any health conditions that prohibit collecting health and covariate data and biospecimens;
* Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.

Where it's running

• Keck School of Medicine, University of Southern California
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Zhanghua Chen, PhD — University of Southern California
• Study coordinator: Zhanghua Chen, PhD
• Email: zhanghuc@usc.edu
• Phone: 323-442-2109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Cilostazol and Aspirin to Prevent Heart and Brain Events in Type 2 Diabetes

  In people with type 2 diabetes and higher cardiovascular risk, researchers are testing whether taking cilostazol plus aspirin can help reduce major heart and brain events.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07719894

• Dapagliflozin to slow coronary plaque progression in type 2 diabetes

  This trial tests whether adding dapagliflozin to standard care can slow or reverse coronary plaque buildup in adults with type 2 diabetes and stable coronary disease.

  Recruiting at 2 sites Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07614230

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.